⌘K

Loading...

/News/RNS

Merger Update: Theramex/Viatris

RNS Announcement

RNS Number : 1986C

Competition and Markets Authority

06 February 2024

Start of CMA Merger Investigation: Theramex/European Rights to Viatris' Femoston and Duphaston products

The Competition and Markets Authority (CMA) is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that merger may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

The CMA announced the launch of its merger inquiry by notice to the Parties on 6 February 2024 and has a deadline of 4 April 2024 for its phase 1 decision.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MERUNAARSVUURAR

RNS metadata

Title: Merger Update: Theramex/Viatris
Time: 14:00:00
Date: 6 Feb 2024
Category: Acquisitions and alliances
ID: 1986C